JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 13 No. 5 328-330
© 1972 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lange, R. C.
Right arrow Articles by Harder, H. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lange, R. C.
Right arrow Articles by Harder, H. C.

Synthesis and Distribution of a Radiolabeled Antitumor Agent: cis-Diamminedichloroplatinum (II)

Robert C. Lange, Richard P. Spencer and Harold C. Harder

Yale University School of Medicine, New Haven, Connecticut

Correspondence: For reprints contact: Richard P. Spencer, Nuclear Medicine Section, Yale University School of Medicine, 333 Cedar St., New Haven, Conn. 06510.

ABSTRACT

The antitumor compound cis-Pt(NH3)2Cl2 was synthesized from 193mPt, and its structure confirmed by three criteria. Following intravenous injection into rabbits, most activity occurred in the kidneys, urine, and liver. In mice a similar distribution was shown with rapid excretion of the radiolabel (79% eliminated by 24 hr). There was little, if any, activity in the brain. The radiolabeled compound presents an almost unique opportunity to trace the distribution of an antineoplastic substance during life.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1972 by the Society of Nuclear Medicine.